Oncologists face challenges in optimizing treatment strategies for metastatic lung cancer patients undergoing PD-1 immunotherapy due to the complexity of the disease and variability in patient response. Traditional methods for assessing treatment response may be subjective or lag behind actual disease progression, hindering timely adjustments to treatment plans. The lack of comprehensive real-world data and AI-driven insights further complicates decision-making.

Onc.AI offers an AI-powered clinical management platform designed to enhance treatment decision-making for metastatic lung cancer patients receiving PD-1 immunotherapy. The platform leverages a large oncology real-world dataset, incorporating diagnostic imaging, EMR data, lab results, and genomics, to generate actionable insights. By applying deep learning to serial CT scans, the platform predicts clinical outcomes and assesses treatment response earlier and more accurately than traditional methods. This enables oncologists to personalize treatment strategies, improve patient outcomes, and fulfill the potential of precision oncology.

AI-driven analysis of diagnostic imaging, including deep learning on serial CT scans

Integration of real-world data from EMR, labs, and genomics for a comprehensive patient profile

Prediction of clinical outcomes in metastatic lung cancer patients undergoing PD-1 immunotherapy

Early assessment of treatment response to enable timely adjustments to treatment plans

Identification of patients who may benefit from alternative treatment strategies

FDA Breakthrough Device Designation for Serial CT Response Score deep learning model

The primary users are medical oncologists treating metastatic lung cancer patients with PD-1 immunotherapy, as well as pharmaceutical companies involved in clinical development.